Survival analysis of patients with locally advanced non-small cell lung cancer treated at the Nu-Med Radiotherapy Center in Elbląg

Q4 Medicine

Nowotwory Pub Date : 2020-07-27 DOI:10.5603/njo.2020.0028

Marcin Kurowicki, K. Osowiecka, S. Nawrocki, Łukasz Cieśliński, B. Szostakiewicz, A. Badzio

{"title":"Survival analysis of patients with locally advanced non-small cell lung cancer treated at the Nu-Med Radiotherapy Center in Elbląg","authors":"Marcin Kurowicki, K. Osowiecka, S. Nawrocki, Łukasz Cieśliński, B. Szostakiewicz, A. Badzio","doi":"10.5603/njo.2020.0028","DOIUrl":null,"url":null,"abstract":"Introduction. The study aimed to report the efficiency of radical radiotherapy and chemoradiotherapy in patients with non-small cell lung cancer (NSCLC) treated in the Nu-Med Radiotherapy Center in Elbląg. Material and methods. Ninety-two patients diagnosed with NSCLC treated between 2013 and 2016 were included in the analysis. Overall survival (OS) was estimated by the Kaplan-Meier method. Results. The 2-year OS for all patients was 36% (median 1.5 years). Two prognostic factors had a significant impact: treatment method and performance status (PS). Patients who underwent concurrent radiochemotherapy and were treated sequentially had a better 2-year OS in comparison with those treated with radiotherapy alone (respectively 46% and 37% vs. 25%, p ≤ 0.05). Patients with PS 0–1 had better OS (median 1.6 years) compared with PS 2 (median 0.7 years, p = 0.04). Other prognostic factors analysed had no impact on OS in our study. Conclusions. The treatment results of our patients are comparable to those in published trials and meta-analyses.","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"19 1","pages":"135-143"},"PeriodicalIF":0.0000,"publicationDate":"2020-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nowotwory","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/njo.2020.0028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction. The study aimed to report the efficiency of radical radiotherapy and chemoradiotherapy in patients with non-small cell lung cancer (NSCLC) treated in the Nu-Med Radiotherapy Center in Elbląg. Material and methods. Ninety-two patients diagnosed with NSCLC treated between 2013 and 2016 were included in the analysis. Overall survival (OS) was estimated by the Kaplan-Meier method. Results. The 2-year OS for all patients was 36% (median 1.5 years). Two prognostic factors had a significant impact: treatment method and performance status (PS). Patients who underwent concurrent radiochemotherapy and were treated sequentially had a better 2-year OS in comparison with those treated with radiotherapy alone (respectively 46% and 37% vs. 25%, p ≤ 0.05). Patients with PS 0–1 had better OS (median 1.6 years) compared with PS 2 (median 0.7 years, p = 0.04). Other prognostic factors analysed had no impact on OS in our study. Conclusions. The treatment results of our patients are comparable to those in published trials and meta-analyses.

查看原文本刊更多论文

在Nu-Med放射治疗中心Elbląg治疗的局部晚期非小细胞肺癌患者的生存分析

介绍。该研究旨在报道在Elbląg Nu-Med放疗中心治疗的非小细胞肺癌(NSCLC)患者的根治性放疗和放化疗的疗效。材料和方法。在2013年至2016年期间接受治疗的92名确诊为非小细胞肺癌的患者被纳入分析。用Kaplan-Meier法估计总生存期(OS)。结果。所有患者的2年OS为36%(中位1.5年)。两个预后因素有显著影响:治疗方法和性能状态(PS)。同时接受放化疗并顺序治疗的患者2年OS较单纯放疗患者更好(分别为46%和37% vs. 25%， p≤0.05)。PS 0-1患者的OS(中位1.6年)优于PS 2患者(中位0.7年，p = 0.04)。在我们的研究中，分析的其他预后因素对OS没有影响。结论。我们患者的治疗结果与已发表的试验和荟萃分析的结果相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nowotwory Medicine-Oncology

CiteScore

0.90

自引率

0.00%

发文量

期刊介绍： NOWOTWORY Journal of Oncology publishes papers which cover all aspects of oncology but concentrates on clinical studies, both research orientated and treatment orientated, rather than on laboratory studies. Contributions are also welcomed from the fields of epidemiology, tumor pathology, radiobiology and radiation physics.